IRLAB Therapeutics AB: Edison Open House Healthcare 2022

IRLAB Therapeutics AB is dedicated to the discovery and development of new drugs for treatment of Parkinson’s disease and other life-altering diseases that affect the central nervous system (CNS). IRLAB strive to transform the everyday life for patients who lack effective treatment options.

• Tell us about the company, its key assets and the particular areas of focus.
• What is IRLAB’s proprietary ISP platform, which leads to these discoveries?
• Tell us about some of the company’s assets.
• Tell us more about the successful deal to out-license your lead asset Mesdopetam to Ipsen in summer 2021.
• At what stage is pirepemat, your next most advanced Parkinson’s asset, in its development timeline?
• Are the other developments in your pipeline also assets focusing on the neglected effects of Parkinson’s disease?
• Which milestones should investors look out for in the coming year?